NCT07052422 2025-07-04
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
Clinical Trials
12 trialsNCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03530085 2020-12-22
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04510610 2020-08-12
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT03793517 2020-03-10
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Peking University People's Hospital
Phase 2/3 Recruiting
NCT02272478 2020-01-23
AML18
Cardiff University
Phase 2/3 Unknown
NCT04123392 2019-10-10
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04098653 2019-09-23
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02472145 2019-03-19
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Janssen Research & Development, LLC
Phase 2/3 Completed
NCT03256071 2017-08-21
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT02159820 2014-06-10
DAC and CT
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT00398983 2013-03-04
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2/3 Completed